Notably, analysis of differentially expressed genes revealed an upregulation of TXNIP, a thiol-oxidoreductase, in the LRRK2-G2019S mutant organoids specifically; inhibition of this gene was able to ameliorate the mutant phenotypes induced by LRRK2-G2019S mutation, indicating the possibility of TXNIP in mediating disease phenotypes of patients with LRRK2-associated PD [113]. The gene discussed is TXNIP; the disease is Parkinson disease.